Furthermore, there is supporting evidence that serum-based liver function markers, including AST, ALT, and ALP levels and the AST to ALT ratio, are associated with AD diagnosis, poor cognitive performance, and increased Aβ deposition (Kellett et al., 2011; Nho et al., 2019; Lu et al., 2021; Ferri et al., 2022; Han et al., 2022; Li et al., 2022). This evidence concerns the gene GPT and Alzheimer disease.